Expert Interview
Understanding the potential of two drugs: SNDX-5613 (revumenib) by Syndax Pharma and Ziftomenib by Kura Oncology, both being developed for treating Acute Myeloid Leukemia with recent data released at the 2022 ASH Conference.
Ticker(s): SNDX, KURAInstitution: University of Minnesota)
- Medical Oncologist and Hematologist & Associate Professor of Medicine, Division of Hematology, Oncology and Transplantation at University of Minnesota.
- Currently manages 40 patients with AML and prescribes Vyxeos.
- Clinical interest in hematologic malignancies and hematopoietic cell transplant ad his research interest is in the conduct of clinical trials and the characterization of infectious complications of hematologic malignancy care.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
